CNCR vs. CEFS

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and CEFS (Saba Closed-End Funds ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while CEFS is a Event Driven fund actively managed by Exchange Traded Concepts. CNCR is passively managed, while CEFS is actively managed. CNCR charges 0.79%/yr vs 1.29%/yr for CEFS.

Performance

CNCR vs. CEFS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Saba Closed-End Funds ETF (CEFS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CEFS

• 1D: 0.29%
• 1M: 5.01%
• YTD: 14.33%
• 6M: 17.93%
• 1Y: 26.67%
• 3Y*: 22.25%
• 5Y*: 13.98%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. CEFS - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
CEFS Saba Closed-End Funds ETF	12.82%

CNCR vs. CEFS - Sectors Allocation Comparison

Sectors	CNCR	CEFS
Healthcare	96.6%	4.6%
Financial Services	3.3%	48.9%
Basic Materials	-	1.6%
Communication Services	-	4.1%
Consumer Cyclical	-	3.3%
Consumer Defensive	-	1.8%
Energy	-	11.2%
Industrials	-	6.7%
Real Estate	-	1.2%
Technology	-	12.4%
Utilities	-	4.2%

Return for Risk

CNCR vs. CEFS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CEFS

CEFS Risk / Return Rank: 85
CEFS Sharpe Ratio Rank: 82
CEFS Sortino Ratio Rank: 87
CEFS Omega Ratio Rank: 84
CEFS Calmar Ratio Rank: 85
CEFS Martin Ratio Rank: 86

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. CEFS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Saba Closed-End Funds ETF (CEFS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	CEFS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.70	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.07	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.80	—

Drawdowns

CNCR vs. CEFS - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum CEFS drawdown of -38.99%. Use the drawdown chart below to compare losses from any high point for CNCR and CEFS.

Drawdown Indicators

	CNCR	CEFS	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-38.99%	+38.99%
Max Drawdown (1Y) Largest decline over 1 year	—	-5.67%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-13.37%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-16.85%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-3.67%	+3.67%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	1.45%	—

Volatility

Volatility by Period

	CNCR	CEFS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	3.28%	—
Volatility (6M) Calculated over the trailing 6-month period	—	8.54%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	9.93%	-9.93%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	13.09%	-13.09%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	15.34%	-15.34%

CNCR vs. CEFS - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than CEFS's 1.29% expense ratio.

Dividends

CNCR vs. CEFS - Dividend Comparison

CNCR has not paid dividends to shareholders, while CEFS's dividend yield for the trailing twelve months is around 7.06%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
CEFS Saba Closed-End Funds ETF	7.06%	7.84%	8.79%	9.20%	11.32%	10.73%	8.61%	8.10%	10.43%	5.02%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, CNCR or CEFS?

On fees, CNCR is cheaper at 0.79% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or CEFS?

CNCR is cheaper with a 0.79% expense ratio, compared with 1.29% for CEFS.

Which ETF pays a higher dividend yield, CNCR or CEFS?

CEFS has the higher dividend yield at 7.06%, compared with 0.00% for CNCR.

What is the main difference between CNCR and CEFS?

CNCR is categorized as Health & Biotech Equities, while CEFS is Event Driven. Their fees differ too: 0.79% for CNCR and 1.29% for CEFS.